BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1, 2025)—

—Record GAAP and non-GAAP operating profit for full year 2025—

—Maintained full year 2026 ORLADEYO revenue guidance between $625 and $645 million—

—Received FDA approval for ORLADEYO oral pellets for patients with HAE Aged 2 to